Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19

BACKGROUND: The COMET-ICE trial demonstrated that sotrovimab clinically and statistically significantly reduces the risk of all-cause > 24-h hospitalization or death due to any cause among patients with COVID-19 at high risk of disease progression. Patient-reported outcomes are important to captu...

Descripción completa

Detalles Bibliográficos
Autores principales: Satram, Sacha, Ghafoori, Parima, Reyes, Carolina M., Keeley, Tom J. H., Birch, Helen J., Brintziki, Dimitra, Aldinger, Melissa, Alexander, Elizabeth, Lopuski, Amanda, Sarkis, Elias H., Gupta, Anil, Shapiro, Adrienne E., Powers, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499766/
https://www.ncbi.nlm.nih.gov/pubmed/37702920
http://dx.doi.org/10.1186/s41687-023-00621-8

Ejemplares similares

Ejemplares similares